HAWK Biosystems are developing a unified and easy to use bioimaging product to enable the discovery and use of a whole new families of breakthrough biomarkers for research, translational medicine and companion diagnostics in the wider clinical and scientific community.

This is Violet 3.0, the all-new QF-Pro® based biomarker quantification platform to answer clinical and research questions alike.

Violet 3.0 is the next generation bioimaging system to elucidate biomarker interactions, activation states and post-translational modifications in both tissue slides and multi-well plates for cells. Violet 3.0 hardware consists of an all-encompassed imaging device, fitted with 4x, 10x and 20x objectives and proprietary optics, coupled to high-speed fluorescence lifetime imaging technology. This permits a user to carry out high-throughput in-situ analysis of biomarker functions in tissue which will require minimal user training and input.

Violet 3.0 allows for advanced image analysis with a user-friendly graphical user interface, designed with simplicity and ease-of-use in mind. Our software allows for full control of all hardware settings and parameters as well as image analysis and visualisation. Moreover, our report generator will present a simplified way to obtain automated reports, delivering results directly to your desktop or mailbox.

Current versions of Violet 3.0 are now being used in-house to provide biomarker discovery, assay development and analytical services to the wider scientific community worldwide, working on companion diagnostics for new treatments and targets.

With Violet 3.0, which will be launched as a stand-alone product in Q3 2023, these research and laboratory teams will now be able to perform QF-Pro® assays on-site.

Contact us now at contact@hawkbiosystems.com to register your interest in Violet 3.0.